A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples

Clinical Chemistry

Volumn 53, Issue 6, 2007, Pages 1067-1074

  Lopez, Mary F ^a   Mikulskis, Alvydas ^a   Kuzdzal, Scott ^a   Golenko, Eva ^a   Petricoin III, Emanuel F ^b   Liotta, Lance A ^b   Patton, Wayne F ^a   Whiteley, Gordon R ^c   Rosenblatt, Kevin ^d   Gurnani, Prem ^d   Nandi, Animesh ^d   Neill, Samuel ^e   Cullen, Stuart ^e   O'Gorman, Martin ^e   Sarracino, David ^f   Lynch, Christopher ^a   Johnson, Andrew ^a   Mckenzie, William ^a   Fishman, David ^f  

^a PERKINELMER INC   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c Clinical Proteomics Reference Laboratory   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Nonlinear Dynamics   (United Kingdom)

^f Harvard Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; ION; PEPTIDE; PEPTIDE FRAGMENT; PLASMA PROTEIN;

ADULT; ALGORITHM; ARTICLE; BIOASSAY; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; REPRODUCIBILITY; SEQUENCE ANALYSIS; SERUM; TANDEM MASS SPECTROMETRY;

BLOOD PROTEINS; CARRIER PROTEINS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PEPTIDES; PROTEIN BINDING; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 34249864811     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.080721     Document Type: Article

References (45)

1. Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200-5.
2. Boyce EA, Kohn EC. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 2005;15(Suppl 3):266-73.
3. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
4. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005;58:308-12.
5. Hortin GL, Jortanl SA, Ritchee, JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22.
6. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3:267-75.
7. Ardekanl AM, Liotta LA, Petricoin EF III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002;2:312-20.
8. Srinivas PR, S. Srivastava S, Hanash S, Wright GL, Proteomics in early detection of cancer. Clin Chem 2001;47:1901-11.
9. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, et al. Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004;55:97-112.
10. Zheng Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
11. Li J, Zheng Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
12. Petricoin EF, Ardekanl AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
13. Hortin GL. The MALDI-TOF mass spectromatric view of the plasma proteome end peptidome. Clin Chem 2006;52:1223-37.
14. Whiteley GR. Proteomic patterns for cancer diagnosis-promise end challenges. Mol BioSyst 2006;2:358-63.
15. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
16. Liotta LA, Lowenthal M, Mahta A, Conrads TP, Veenstra TD, Fishman DA, et al. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005;97:310-14.
17. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-5.
18. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30.
19. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Areujo RP, Hood BL, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005;51:1933-45.
20. Diamandis EP. Peptidomics for cancer diagnosis: present and future. J Proteome Res 2006;9:2079-82.
21. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-103.
22. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
23. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, et al. The human serum proteome: displey of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003;3:1345-64.
24. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002;1:947-55.
25. Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19:242-7.
26. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003;3:243-8.
27. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF III, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003;19:1-10.
28. Lopez MF, Mikulskis A, Kuzdzal S, Bennett D, Kelly J, Golenko E, et al. High-resolution serum proteomic profiling of Alzheimer's disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005;51:1946-54.
29. Zhou M, Lucas DA, Chan KG, Issaq HJ, Petricoin EF III, Liotta LA, et al. An investigation into the human serum "interactome". Electrophoresis 2004;25:1289-98.
30. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
31. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005;4:972-81.
32. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: An R Package for visualizing the performance of scoring classifiers. http://rocr.bioinf.mpi-sb. mpg.de (accessed January 2006).
33. Hastle TJ, Tibshirani R, Buja A. Flexible Discriminant Analysis by Optimal Scoring. J Am Stat Assoc 1994;89:1255-70.
34. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005;21:3294-3300.
35. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Keufman AJ, Singh B, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006;126:269-83.
36. DeSouza L, Diehl G, Rodrigues MJ, Guo J, Romaschin AD, Colgan TJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and clCAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005;4:377-86.
37. Chen H, Wang M, Wang XY, Gao S, Wang J, Guan XM. Identification of differential genes in ovarian cancer using representational difference analysis of cDNA. Chin Med Sci J 2005;3:185-9.
38. Sieja K, Stanosz S, von Mach-Szczypinski J, Olewniczak S, Stanosz M. Concentration of histamine in serum and tissues of the primary ductal breast cancers in women. Breast 2005;14:236-41.
39. Bloor BK, Tidman N, Leigh IM, Odell E, Dogan B, Wollina U, et al. Expression of keratin K2e in cutaneous and oral lesions: association with keratinocyte activation, proliferation, and keratinization. Am J Pathol 2003;162:963-75.
40. Juang CM, Yang YH, Lo WH, Lai CR, Hsieh SL, Yuan CC. Altered mRNA expressions of sialyltransferases in ovarian cancers. Wang PH, Lee WL, Gynecol Oncol 2005;99:631-9.
41. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Contrads TP, et al. The human plasma proteome. Molec Cell Proteom 2004;3:311-26.
42. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35:103-10.
43. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(Suppl 3):274-81.
44. Kumar R, Hung M-C. Signaling intricacies take center stage in cancer cells. Cancer Res 2005;65:2511-5.
45. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;17:4589-96.